Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2008 by Rambam Health Care Campus.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00660751
First received: April 15, 2008
Last updated: April 16, 2008
Last verified: February 2008

April 15, 2008
April 16, 2008
August 2007
August 2009   (final data collection date for primary outcome measure)
level of DNIC [ Time Frame: 1 week ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00660751 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control
The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control

The role of central serotonergic and adrenergic systems in the effectiveness of DNIC (Diffuse Noxious Inhibitory Control) will be tested before and after taking Duloxetine and Placebo in a double blind study.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Healthy
Drug: Duloxetine
SNRIs
  • Active Comparator: 1
    Intervention: Drug: Duloxetine
  • Placebo Comparator: 2
    Intervention: Drug: Duloxetine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
Not Provided
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers
  • age 18-80
  • no chronic disease

Exclusion Criteria:

  • Subjects who suffer from chronic pain / pain syndrome
  • use of anti-depressant or anti-psychotic drugs
  • food/ drugs sensitivity
  • breast feeding
Both
18 Years to 80 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00660751
DNIC01CTIL
Not Provided
Prof. David Yarnitsky/ Head of Neurology Department, Rambam Health Care Campus
Rambam Health Care Campus
Not Provided
Principal Investigator: Prof. David Yarnitsky
Rambam Health Care Campus
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP